eFFECTOR Therapeutics (EFTR) Short Interest Ratio & Short Volume

Short interest is the volume of eFFECTOR Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 128,300 shares of EFTR short. 3.12% of eFFECTOR Therapeutics' shares are currently sold short. Learn More on eFFECTOR Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.12% of eFFECTOR Therapeutics' floating shares are currently sold short.

eFFECTOR Therapeutics saw a drop in short interest in April. As of April 30th, there was short interest totaling 128,300 shares, a drop of 47.4% from the previous total of 244,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

eFFECTOR Therapeutics currently has issued a total of 3,690,000 shares. Some of eFFECTOR Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. eFFECTOR Therapeutics currently has a public float of 4,110,000 shares.

3.12% of eFFECTOR Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to eFFECTOR Therapeutics: Vaccinex, Inc. (2.40%), Hepion Pharmaceuticals, Inc. (1.19%), Cyclerion Therapeutics, Inc. (0.99%), Pasithea Therapeutics Corp. (1.34%), Bionomics Limited (1.45%), Virios Therapeutics, Inc. (1.24%), Cadrenal Therapeutics, Inc. (0.80%), Processa Pharmaceuticals, Inc. (24.82%), TransCode Therapeutics, Inc. (2.29%), Trevena, Inc. (0.08%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

Short selling EFTR is an investing strategy that aims to generate trading profit from eFFECTOR Therapeutics as its price is falling. EFTR shares are trading down $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for eFFECTOR Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EFTR, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EFTR, twice per month. The most recent reporting period available is April, 30 2024.